ID   KS6A1_HUMAN             Reviewed;         735 AA.
AC   Q15418; A6NGG4; A8K9K7; B2RDY8; B7Z5J0; E9PRI4; Q5SVM5; Q5SVM8; Q5SVM9;
AC   Q96C05; Q9BQK2;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   12-OCT-2022, entry version 224.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-1;
DE            Short=S6K-alpha-1;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 1;
DE            Short=p90-RSK 1;
DE            Short=p90RSK1;
DE            Short=p90S6K;
DE   AltName: Full=MAP kinase-activated protein kinase 1a;
DE            Short=MAPK-activated protein kinase 1a;
DE            Short=MAPKAP kinase 1a;
DE            Short=MAPKAPK-1a;
DE   AltName: Full=Ribosomal S6 kinase 1;
DE            Short=RSK-1;
GN   Name=RPS6KA1; Synonyms=MAPKAPK1A, RSK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-335.
RX   PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351;
RA   Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.;
RT   "Human rsk isoforms: cloning and characterization of tissue-specific
RT   expression.";
RL   Am. J. Physiol. 266:C351-C359(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Testis, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [7]
RP   FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-221; THR-359;
RP   SER-363; SER-380; THR-573 AND SER-732.
RX   PubMed=9430688; DOI=10.1074/jbc.273.3.1496;
RA   Dalby K.N., Morrice N., Caudwell F.B., Avruch J., Cohen P.;
RT   "Identification of regulatory phosphorylation sites in mitogen-activated
RT   protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible
RT   by MAPK.";
RL   J. Biol. Chem. 273:1496-1505(1998).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=10679322; DOI=10.1016/s0960-9822(00)00310-9;
RA   Shimamura A., Ballif B.A., Richards S.A., Blenis J.;
RT   "Rsk1 mediates a MEK-MAP kinase cell survival signal.";
RL   Curr. Biol. 10:127-135(2000).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CEBPB.
RX   PubMed=11684016; DOI=10.1016/s1097-2765(01)00374-4;
RA   Buck M., Poli V., Hunter T., Chojkier M.;
RT   "C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase
RT   inhibitory box critical for cell survival.";
RL   Mol. Cell 8:807-816(2001).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF ETV1/ER81, AND INTERACTION WITH ETV1/ER81.
RX   PubMed=12213813; DOI=10.1074/jbc.m205501200;
RA   Wu J., Janknecht R.;
RT   "Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6
RT   kinase 1 and protein kinase A.";
RL   J. Biol. Chem. 277:42669-42679(2002).
RN   [11]
RP   INTERACTION WITH MAPK1 OR MAPK3.
RX   PubMed=12832467; DOI=10.1128/mcb.23.14.4796-4804.2003;
RA   Roux P.P., Richards S.A., Blenis J.;
RT   "Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular
RT   signal-regulated kinase docking and RSK activity.";
RL   Mol. Cell. Biol. 23:4796-4804(2003).
RN   [12]
RP   FUNCTION, INTERACTION WITH FGFR1, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15117958; DOI=10.1074/jbc.m311144200;
RA   Hu Y., Fang X., Dunham S.M., Prada C., Stachowiak E.K., Stachowiak M.K.;
RT   "90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast
RT   growth factor receptor 1 (FGFR1): role in FGFR1 signaling.";
RL   J. Biol. Chem. 279:29325-29335(2004).
RN   [13]
RP   FUNCTION IN MTOR SIGNALING, AND INTERACTION WITH TSC2.
RX   PubMed=15342917; DOI=10.1073/pnas.0405659101;
RA   Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J.;
RT   "Tumor-promoting phorbol esters and activated Ras inactivate the tuberous
RT   sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13489-13494(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK1.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77.
RX   PubMed=16223362; DOI=10.1042/bj20050967;
RA   Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.;
RT   "Nur77 is phosphorylated in cells by RSK in response to mitogenic
RT   stimulation.";
RL   Biochem. J. 393:715-724(2006).
RN   [16]
RP   FUNCTION IN TRANSLATION REGULATION, AND FUNCTION IN PHOSPHORYLATION OF
RP   EIF4B.
RX   PubMed=16763566; DOI=10.1038/sj.emboj.7601166;
RA   Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J.,
RA   Hershey J.W., Blenis J., Pende M., Sonenberg N.;
RT   "The mTOR/PI3K and MAPK pathways converge on eIF4B to control its
RT   phosphorylation and activity.";
RL   EMBO J. 25:2781-2791(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6.
RX   PubMed=17360704; DOI=10.1074/jbc.m700906200;
RA   Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J.,
RA   Sonenberg N., Blenis J.;
RT   "RAS/ERK signaling promotes site-specific ribosomal protein S6
RT   phosphorylation via RSK and stimulates cap-dependent translation.";
RL   J. Biol. Chem. 282:14056-14064(2007).
RN   [19]
RP   FUNCTION IN MTOR SIGNALING.
RX   PubMed=18722121; DOI=10.1016/j.cub.2008.07.078;
RA   Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P.,
RA   Roux P.P.;
RT   "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
RT   mediated raptor phosphorylation.";
RL   Curr. Biol. 18:1269-1277(2008).
RN   [20]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=18508509; DOI=10.2741/3003;
RA   Carriere A., Ray H., Blenis J., Roux P.P.;
RT   "The RSK factors of activating the Ras/MAPK signaling cascade.";
RL   Front. Biosci. 13:4258-4275(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363 AND SER-380, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=18813292; DOI=10.1038/nrm2509;
RA   Anjum R., Blenis J.;
RT   "The RSK family of kinases: emerging roles in cellular signalling.";
RL   Nat. Rev. Mol. Cell Biol. 9:747-758(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363; SER-369 AND
RP   SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-307; THR-359;
RP   SER-363; SER-369 AND SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359 AND SER-363, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-363; SER-369 AND
RP   SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363 AND SER-380, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF EPHA2.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S.,
RA   Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine phosphorylation
RT   of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [31]
RP   INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN
RP   ORF45 (MICROBIAL INFECTION), AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=30842327; DOI=10.1128/jvi.02154-18;
RA   Li X., Huang L., Xiao Y., Yao X., Long X., Zhu F., Kuang E.;
RT   "Development of an ORF45-Derived Peptide To Inhibit the Sustained RSK
RT   Activation and Lytic Replication of Kaposi's Sarcoma-Associated
RT   Herpesvirus.";
RL   J. Virol. 93:0-0(2019).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 33-353 IN COMPLEX WITH INHIBITOR.
RX   PubMed=17965187; DOI=10.1110/ps.073123707;
RA   Ikuta M., Kornienko M., Byrne N., Reid J.C., Mizuarai S., Kotani H.,
RA   Munshi S.K.;
RT   "Crystal structures of the N-terminal kinase domain of human RSK1 bound to
RT   three different ligands: Implications for the design of RSK1 specific
RT   inhibitors.";
RL   Protein Sci. 16:2626-2635(2007).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-335.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK
CC       (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and
CC       stress-induced activation of the transcription factors CREB1, ETV1/ER81
CC       and NR4A1/NUR77, regulates translation through RPS6 and EIF4B
CC       phosphorylation, and mediates cellular proliferation, survival, and
CC       differentiation by modulating mTOR signaling and repressing pro-
CC       apoptotic function of BAD and DAPK1. In fibroblast, is required for
CC       EGF-stimulated phosphorylation of CREB1, which results in the
CC       subsequent transcriptional activation of several immediate-early genes.
CC       In response to mitogenic stimulation (EGF and PMA), phosphorylates and
CC       activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the
CC       cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the
CC       transcription regulation of several genes by phosphorylating GSK3B at
CC       'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to
CC       serum or EGF via an mTOR-independent mechanism and promotes translation
CC       initiation by facilitating assembly of the pre-initiation complex. In
CC       response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for
CC       the EIF3 complex and stimulating cap-dependent translation. Is involved
CC       in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2
CC       at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR
CC       signaling, and mediates phosphorylation of RPTOR, which regulates
CC       mTORC1 activity and may promote rapamycin-sensitive signaling
CC       independently of the PI3K/AKT pathway. Mediates cell survival by
CC       phosphorylating the pro-apoptotic proteins BAD and DAPK1 and
CC       suppressing their pro-apoptotic function. Promotes the survival of
CC       hepatic stellate cells by phosphorylating CEBPB in response to the
CC       hepatotoxin carbon tetrachloride (CCl4). Mediates induction of
CC       hepatocyte prolifration by TGFA through phosphorylation of CEBPB (By
CC       similarity). Is involved in cell cycle regulation by phosphorylating
CC       the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3
CC       proteins and prevents its translocation to the nucleus and inhibition
CC       of G1 progression. Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2
CC       signaling pathway controls cell migration (PubMed:26158630).
CC       {ECO:0000250|UniProtKB:P18653, ECO:0000250|UniProtKB:Q63531,
CC       ECO:0000269|PubMed:10679322, ECO:0000269|PubMed:11684016,
CC       ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:15117958,
CC       ECO:0000269|PubMed:15342917, ECO:0000269|PubMed:16213824,
CC       ECO:0000269|PubMed:16223362, ECO:0000269|PubMed:16763566,
CC       ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121,
CC       ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:9430688}.
CC   -!- FUNCTION: (Microbial infection) Promotes the late transcription and
CC       translation of viral lytic genes during Kaposi's sarcoma-associated
CC       herpesvirus/HHV-8 infection, when constitutively activated.
CC       {ECO:0000269|PubMed:30842327}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation,
CC       phosphorylated at Thr-573 in the C-terminal kinase domain (CTKD) by
CC       MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates
CC       Ser-380, allowing binding of PDPK1, which in turn phosphorylates Ser-
CC       221 in the N-terminal kinase domain (NTDK) leading to the full
CC       activation of the protein and subsequent phosphorylation of the
CC       substrates by the NTKD. {ECO:0000269|PubMed:15117958,
CC       ECO:0000269|PubMed:9430688}.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells. Transiently dissociates following mitogenic
CC       stimulation. Interacts with ETV1/ER81 and FGFR1.
CC       {ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:12832467,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:15342917,
CC       ECO:0000269|PubMed:17965187}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma-
CC       associated herpesvirus/HHV-8 protein ORF45; this interaction allows
CC       RPS6KA1 activation. {ECO:0000269|PubMed:30842327}.
CC   -!- INTERACTION:
CC       Q15418; O43823: AKAP8; NbExp=5; IntAct=EBI-963034, EBI-1237481;
CC       Q15418; P46527: CDKN1B; NbExp=2; IntAct=EBI-963034, EBI-519280;
CC       Q15418; P08238: HSP90AB1; NbExp=4; IntAct=EBI-963034, EBI-352572;
CC       Q15418; P28482: MAPK1; NbExp=7; IntAct=EBI-963034, EBI-959949;
CC       Q15418; P04271: S100B; NbExp=2; IntAct=EBI-963034, EBI-458391;
CC       Q15418; Q14160: SCRIB; NbExp=3; IntAct=EBI-963034, EBI-357345;
CC       Q15418; P50552: VASP; NbExp=4; IntAct=EBI-963034, EBI-748201;
CC       Q15418; A1JU68: yopM; Xeno; NbExp=3; IntAct=EBI-963034, EBI-26365850;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15418-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15418-2; Sequence=VSP_041380;
CC       Name=3;
CC         IsoId=Q15418-3; Sequence=VSP_041580;
CC       Name=4 {ECO:0000305};
CC         IsoId=Q15418-4; Sequence=VSP_057469;
CC   -!- PTM: Activated by phosphorylation at Ser-221 by PDPK1.
CC       Autophosphorylated on Ser-380, as part of the activation process. May
CC       be phosphorylated at Thr-359 and Ser-363 by MAPK1/ERK2 and MAPK3/ERK1.
CC       {ECO:0000269|PubMed:9430688}.
CC   -!- PTM: N-terminal myristoylation results in an activated kinase in the
CC       absence of added growth factors.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RPS6KA1ID43477ch1p36.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L07597; AAC82497.1; -; mRNA.
DR   EMBL; AK292722; BAF85411.1; -; mRNA.
DR   EMBL; AK299007; BAH12926.1; -; mRNA.
DR   EMBL; AK315730; BAG38085.1; -; mRNA.
DR   EMBL; AL109743; CAC36348.1; -; Genomic_DNA.
DR   EMBL; AL627313; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07799.1; -; Genomic_DNA.
DR   EMBL; BC014966; AAH14966.1; -; mRNA.
DR   CCDS; CCDS284.1; -. [Q15418-1]
DR   CCDS; CCDS30649.1; -. [Q15418-2]
DR   CCDS; CCDS81286.1; -. [Q15418-4]
DR   PIR; I51901; I51901.
DR   RefSeq; NP_001006666.1; NM_001006665.1. [Q15418-2]
DR   RefSeq; NP_001317370.1; NM_001330441.1. [Q15418-4]
DR   RefSeq; NP_002944.2; NM_002953.3. [Q15418-1]
DR   PDB; 2WNT; X-ray; 2.40 A; A/B=413-719.
DR   PDB; 2Z7Q; X-ray; 2.00 A; A=33-353.
DR   PDB; 2Z7R; X-ray; 2.00 A; A=33-353.
DR   PDB; 2Z7S; X-ray; 2.10 A; A=33-353.
DR   PDB; 3RNY; X-ray; 2.70 A; A/B=411-735.
DR   PDB; 3TEI; X-ray; 2.40 A; B=712-735.
DR   PDB; 4H3P; X-ray; 2.30 A; B/E=712-735.
DR   PDB; 4NIF; X-ray; 2.15 A; A/D=411-735.
DR   PDB; 5CSF; X-ray; 2.40 A; C=683-735.
DR   PDB; 5CSI; X-ray; 2.13 A; C=689-735.
DR   PDB; 5CSJ; X-ray; 2.70 A; C=696-735.
DR   PDB; 5CSN; X-ray; 2.95 A; C=683-720.
DR   PDB; 5N7D; X-ray; 2.30 A; C=688-735.
DR   PDB; 5N7F; X-ray; 2.30 A; C=688-735.
DR   PDB; 5N7G; X-ray; 2.95 A; C=729-735.
DR   PDB; 5V61; X-ray; 2.20 A; I=713-729.
DR   PDB; 5V62; X-ray; 1.90 A; I=713-729.
DR   PDB; 6TWY; X-ray; 2.30 A; C=725-735.
DR   PDBsum; 2WNT; -.
DR   PDBsum; 2Z7Q; -.
DR   PDBsum; 2Z7R; -.
DR   PDBsum; 2Z7S; -.
DR   PDBsum; 3RNY; -.
DR   PDBsum; 3TEI; -.
DR   PDBsum; 4H3P; -.
DR   PDBsum; 4NIF; -.
DR   PDBsum; 5CSF; -.
DR   PDBsum; 5CSI; -.
DR   PDBsum; 5CSJ; -.
DR   PDBsum; 5CSN; -.
DR   PDBsum; 5N7D; -.
DR   PDBsum; 5N7F; -.
DR   PDBsum; 5N7G; -.
DR   PDBsum; 5V61; -.
DR   PDBsum; 5V62; -.
DR   PDBsum; 6TWY; -.
DR   AlphaFoldDB; Q15418; -.
DR   SMR; Q15418; -.
DR   BioGRID; 112109; 185.
DR   DIP; DIP-29987N; -.
DR   ELM; Q15418; -.
DR   IntAct; Q15418; 67.
DR   MINT; Q15418; -.
DR   STRING; 9606.ENSP00000435412; -.
DR   BindingDB; Q15418; -.
DR   ChEMBL; CHEMBL2553; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB04751; Purvalanol A.
DR   DrugCentral; Q15418; -.
DR   GuidetoPHARMACOLOGY; 1527; -.
DR   GlyGen; Q15418; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q15418; -.
DR   PhosphoSitePlus; Q15418; -.
DR   BioMuta; RPS6KA1; -.
DR   DMDM; 20178306; -.
DR   UCD-2DPAGE; Q15418; -.
DR   EPD; Q15418; -.
DR   jPOST; Q15418; -.
DR   MassIVE; Q15418; -.
DR   MaxQB; Q15418; -.
DR   PaxDb; Q15418; -.
DR   PeptideAtlas; Q15418; -.
DR   PRIDE; Q15418; -.
DR   ProteomicsDB; 23324; -.
DR   ProteomicsDB; 60583; -. [Q15418-1]
DR   ProteomicsDB; 60584; -. [Q15418-2]
DR   ProteomicsDB; 60585; -. [Q15418-3]
DR   Antibodypedia; 2073; 1692 antibodies from 44 providers.
DR   DNASU; 6195; -.
DR   Ensembl; ENST00000374168.7; ENSP00000363283.2; ENSG00000117676.14. [Q15418-1]
DR   Ensembl; ENST00000526792.5; ENSP00000431651.1; ENSG00000117676.14. [Q15418-3]
DR   Ensembl; ENST00000530003.5; ENSP00000432281.1; ENSG00000117676.14. [Q15418-4]
DR   Ensembl; ENST00000531382.5; ENSP00000435412.1; ENSG00000117676.14. [Q15418-2]
DR   Ensembl; ENST00000628081.2; ENSP00000487553.1; ENSG00000281877.3. [Q15418-4]
DR   Ensembl; ENST00000628256.2; ENSP00000487349.1; ENSG00000281877.3. [Q15418-2]
DR   Ensembl; ENST00000629832.3; ENSP00000486881.1; ENSG00000281877.3. [Q15418-1]
DR   Ensembl; ENST00000631108.2; ENSP00000487166.1; ENSG00000281877.3. [Q15418-3]
DR   GeneID; 6195; -.
DR   KEGG; hsa:6195; -.
DR   MANE-Select; ENST00000374168.7; ENSP00000363283.2; NM_002953.4; NP_002944.2.
DR   UCSC; uc001bmr.2; human. [Q15418-1]
DR   UCSC; uc057dso.1; human.
DR   CTD; 6195; -.
DR   DisGeNET; 6195; -.
DR   GeneCards; RPS6KA1; -.
DR   HGNC; HGNC:10430; RPS6KA1.
DR   HPA; ENSG00000117676; Low tissue specificity.
DR   MIM; 601684; gene.
DR   neXtProt; NX_Q15418; -.
DR   OpenTargets; ENSG00000117676; -.
DR   PharmGKB; PA34845; -.
DR   VEuPathDB; HostDB:ENSG00000117676; -.
DR   eggNOG; KOG0603; Eukaryota.
DR   GeneTree; ENSGT00940000159314; -.
DR   HOGENOM; CLU_000288_58_0_1; -.
DR   InParanoid; Q15418; -.
DR   OMA; ILEHSWV; -.
DR   OrthoDB; 1132245at2759; -.
DR   PhylomeDB; Q15418; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q15418; -.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   SABIO-RK; Q15418; -.
DR   SignaLink; Q15418; -.
DR   SIGNOR; Q15418; -.
DR   BioGRID-ORCS; 6195; 26 hits in 1112 CRISPR screens.
DR   ChiTaRS; RPS6KA1; human.
DR   EvolutionaryTrace; Q15418; -.
DR   GeneWiki; RPS6KA1; -.
DR   GenomeRNAi; 6195; -.
DR   Pharos; Q15418; Tchem.
DR   PRO; PR:Q15418; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q15418; protein.
DR   Bgee; ENSG00000117676; Expressed in blood and 101 other tissues.
DR   ExpressionAtlas; Q15418; baseline and differential.
DR   Genevisible; Q15418; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome.
DR   GO; GO:0072574; P:hepatocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0043620; P:regulation of DNA-templated transcription in response to stress; TAS:UniProtKB.
DR   GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd05582; STKc_RSK_N; 1.
DR   DisProt; DP01508; -.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR041906; RSK_N.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cytoplasm;
KW   Host-virus interaction; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Stress response; Transferase.
FT   CHAIN           1..735
FT                   /note="Ribosomal protein S6 kinase alpha-1"
FT                   /id="PRO_0000086198"
FT   DOMAIN          62..321
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          322..391
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          418..675
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        187
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        535
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         68..76
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         94
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         424..432
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         447
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         54
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         221
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000305|PubMed:9430688"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         359
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9430688,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9430688,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         380
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9430688,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         573
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9430688"
FT   MOD_RES         732
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:9430688"
FT   VAR_SEQ         1..92
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041580"
FT   VAR_SEQ         1..36
FT                   /note="MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPSK -> MEQDPKPPRLRL
FT                   WALIPWLPRKQRPRISQTSLPVPGPGSGPQRDS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041380"
FT   VAR_SEQ         1..35
FT                   /note="MPLAQLKEPWPLMELVPLDPENGQTSGEEAGLQPS -> MQTPADFPRVERD
FT                   LVPCPR (in isoform 4)"
FT                   /id="VSP_057469"
FT   VARIANT         335
FT                   /note="K -> T (in dbSNP:rs2229712)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8141249"
FT                   /id="VAR_021864"
FT   CONFLICT        609
FT                   /note="A -> T (in Ref. 2; BAF85411)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        619
FT                   /note="S -> G (in Ref. 2; BAF85411)"
FT                   /evidence="ECO:0000305"
FT   HELIX           59..61
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          62..71
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          74..81
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          83..86
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          90..96
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          127..133
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          136..141
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           149..156
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           161..180
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           190..192
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          193..195
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          197..199
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           226..228
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           231..234
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           241..257
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           267..276
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           287..296
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   TURN            301..303
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          307..310
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           312..316
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   HELIX           326..330
FT                   /evidence="ECO:0007829|PDB:2Z7Q"
FT   STRAND          418..427
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          430..437
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   TURN            438..441
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          442..450
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   TURN            451..453
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           457..466
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          475..480
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          482..490
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           497..501
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          503..505
FT                   /evidence="ECO:0007829|PDB:3RNY"
FT   HELIX           509..528
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           538..540
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          541..547
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           550..552
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   STRAND          553..555
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   TURN            574..576
FT                   /evidence="ECO:0007829|PDB:2WNT"
FT   HELIX           583..609
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           622..631
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           639..642
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           646..655
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           660..662
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           666..671
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           673..676
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           678..680
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           691..706
FT                   /evidence="ECO:0007829|PDB:4NIF"
FT   HELIX           717..719
FT                   /evidence="ECO:0007829|PDB:5V62"
FT   HELIX           721..725
FT                   /evidence="ECO:0007829|PDB:5V62"
FT   STRAND          733..735
FT                   /evidence="ECO:0007829|PDB:5N7D"
SQ   SEQUENCE   735 AA;  82723 MW;  765731A4442A53DF CRC64;
     MPLAQLKEPW PLMELVPLDP ENGQTSGEEA GLQPSKDEGV LKEISITHHV KAGSEKADPS
     HFELLKVLGQ GSFGKVFLVR KVTRPDSGHL YAMKVLKKAT LKVRDRVRTK MERDILADVN
     HPFVVKLHYA FQTEGKLYLI LDFLRGGDLF TRLSKEVMFT EEDVKFYLAE LALGLDHLHS
     LGIIYRDLKP ENILLDEEGH IKLTDFGLSK EAIDHEKKAY SFCGTVEYMA PEVVNRQGHS
     HSADWWSYGV LMFEMLTGSL PFQGKDRKET MTLILKAKLG MPQFLSTEAQ SLLRALFKRN
     PANRLGSGPD GAEEIKRHVF YSTIDWNKLY RREIKPPFKP AVAQPDDTFY FDTEFTSRTP
     KDSPGIPPSA GAHQLFRGFS FVATGLMEDD GKPRAPQAPL HSVVQQLHGK NLVFSDGYVV
     KETIGVGSYS ECKRCVHKAT NMEYAVKVID KSKRDPSEEI EILLRYGQHP NIITLKDVYD
     DGKHVYLVTE LMRGGELLDK ILRQKFFSER EASFVLHTIG KTVEYLHSQG VVHRDLKPSN
     ILYVDESGNP ECLRICDFGF AKQLRAENGL LMTPCYTANF VAPEVLKRQG YDEGCDIWSL
     GILLYTMLAG YTPFANGPSD TPEEILTRIG SGKFTLSGGN WNTVSETAKD LVSKMLHVDP
     HQRLTAKQVL QHPWVTQKDK LPQSQLSHQD LQLVKGAMAA TYSALNSSKP TPQLKPIESS
     ILAQRRVRKL PSTTL
//
